PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17459751-3	2007	The purpose of the studies presented here was to describe some of the preclinical development of idursulfase using the I2S knock-out mouse model of MPS II designed to study the effect of dose and various dosing regimens of idursulfase on urine and tissue GAG levels.	Glycosaminoglycans	255-258	iduronate 2-sulfatase	Homo sapiens	97-108	
17459751-3	2007	The purpose of the studies presented here was to describe some of the preclinical development of idursulfase using the I2S knock-out mouse model of MPS II designed to study the effect of dose and various dosing regimens of idursulfase on urine and tissue GAG levels.	Glycosaminoglycans	255-258	iduronate 2-sulfatase	Homo sapiens	223-234	
17459751-6	2007	Results showed that idursulfase, at several doses and at several dosing frequencies, caused a reduction in tissue and urine GAG levels in a dose-dependent manner.	Glycosaminoglycans	124-127	iduronate 2-sulfatase	Homo sapiens	20-31	
17459751-7	2007	These studies also demonstrated that after IV administration, idursulfase is biologically active in the IdS-KO mouse model and is transported to key target tissues, reaching the lysosomes in an active form, and degrading the accumulated GAG.	Glycosaminoglycans	237-240	iduronate 2-sulfatase	Homo sapiens	62-73